Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients. Methods: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched). Results: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARDnaive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from 1.67 ± 2.12 pg/mL at baseline to 2.51 ± 3.03 pg/mL, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755). Conclusions: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.
Abstract
Background/Aims: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients. Methods: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched). Results: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARDnaive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from 1.67 ± 2.12 pg/mL at baseline to 2.51 ± 3.03 pg/mL, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755). Conclusions: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.
참고문헌 (22)
- Walsh NC, "Rheumatic diseases: the effects of inflammation on bone", Immunol Rev, 208, pp.228~251 (2005)
- Wijbrandts CA, "Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy:arrest of bone loss", Ann Rheum Dis, 68, pp.373~376 (2009)
- Saidenberg-Kermanac’h N, "TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis", Bone, 35, pp.1200~1207 (2004)
- Diarra D, "Dickkopf-1 is a master regulator of joint remodeling", Nat Med, 13, pp.156~163 (2007)
- Garnero P, "Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept", J Rheumatol, 35, pp.2313~2315 (2008)
- Vis M, "Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab", Arthritis Rheum, 48, pp.2996~2997 (2003)
- Vis M, "Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis", Ann Rheum Dis, 65, pp.1495~1499 (2006)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- van Gestel AM, "Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization", International League Against Rheumatism Criteria, 1996, pp.39, 34~40
- Uehara R, "Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy", J Rheumatol, 28, pp.251~256 (2001)
- Torikai E, "The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis", Mod Rheumatol, 16, pp.350~354 (2006)
- Ton FN, "Effects of low-dose prednisone on bone metabolism", J Bone Miner Res, 20, pp.464~470 (2005)
- Rosen HN, "Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy", Calcif Tissue Int, 66, pp.100~103 (2000)
- Li X, "Sclerostin binds to LRP5", 6and antagonizes canonical Wnt signaling, 2005, pp.280, 19883~19887
- Semenov M, "SOST is a ligand for LRP5", LRP6and a Wnt signaling inhibitor, 2005, pp.280, 26770~26775
- Ellies DL, "Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity", J Bone Miner Res, 21, pp.1738~1749 (2006)
- ten Dijke P, "Osteocyte-derived sclerostin inhibits bone formation:its role in bone morphogenetic protein and Wnt signaling", J Bone Joint Surg Am, 90(Suppl 1), pp.31~35 (2008)
- Yasunori K, "Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis", Clin Rheumatol, 27, pp.1093~1101 (2008)
- Polyzos SA, "Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women: the six-month effect of risedronate and teriparatide", Osteoporos Int, 23, pp.1171~1176 (2012)
- Terpos E, "Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis", Clin Exp Rheumatol, 29, pp.921~925 (2011)
- Modder UI, "Regulation of circulating sclerostin levels by sex steroids in women and in men", J Bone Miner Res, 26, pp.27~34 (2011)
- Sennels H, "Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate", Scand J Rheumatol, 37, pp.241~247 (2008)